Table S2. from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer

Key Points

• The effectiveness of FoundationOne Liquid CDx for detecting BRAF V600E was validated in colorectal cancer cases.
• Plasma samples sourced from diverse groups help ensure reliability in BRAF V600E detection.
• Sample sizes and attributes from testing are crucial for validating clinical applications of the liquid biopsy technology.
• This assessment highlights the importance of robust liquid biopsy methodologies in oncology diagnostics.